Lifecore Biomedical, Inc. (LFCR) stock
Close on Nov 12, 2026Market cap $242.26MP/E –Yield –
Lifecore Biomedical, Inc. grew revenue 0.5% to $128.87M over the twelve months to May 25, 2025. Free cash flow was -$13.62M. At the latest close the market valued the company at $242.26M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $242.26M
- P/E ratio
- –
- Price to sales
- 1.88
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -5.62%
Fundamentals
- Revenue
- $128.87M
- Net income
- -$38.72M
- EPS, diluted
- -$1.27
- Free cash flow
- -$13.62M
- Book value per share
- -$1.94
- Diluted shares
- 38M
Trading
- Previous close
- $6.40
- Open
- $6.38
- Day's range
- $6.38 – $6.40
- Volume
- 109,891
- Average volume (20 days)
- 452,377
- Index membership
- Russell 2000 (since Sep 2024)
- Beta (5 years)
- 1.05
- 52-week range
- $3.63 – $8.98
- RSI (14 days)
- 62.6
- Volatility (1 year)
- 80.0%
- Relative volume
- 0.33×
- WACC
- 10.1%
Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2010, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | LFCR | S&P 500 | Difference | LFCR per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -0.6% | -2.7% | +2.1 pts | ||
| 3 months | +34.2% | -1.7% | +35.9 pts | ||
| Year to date | -21.8% | +11.9% | −33.7 pts | ||
| 1 year | -22.1% | +12.0% | −34.1 pts | ||
| 3 years | -8.6% | +78.2% | −86.7 pts | -2.9% | +21.2% |
| 5 years | -32.7% | +73.2% | −105.9 pts | -7.6% | +11.6% |
| 10 years | -55.6% | +309.6% | −365.2 pts | -7.8% | +15.1% |
Fifteen years at a glance
Fiscal years 2011 to 2025, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Lifecore Biomedical filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Update
- Update
- Results
- Results
About Lifecore Biomedical
Pharmaceutical Preparations
Lifecore Biomedical, Inc. is a contract development and manufacturing organization that specializes in the development, manufacturing, and aseptic filling of sterile injectable pharmaceutical drugs and medical devices. The company manufactures pharmaceutical-grade hyaluronic acid through bacterial fermentation in both bulk and filled formats such as syringes, vials, and cartridges, alongside non-hyaluronic acid formulations. Its service offerings include formulation development, analytical method validation, process scale-up, stability testing, and clinical trial material production. Lifecore manages its operations through a single integrated business segment. The company serves emerging and global biopharmaceutical and biotechnology firms, as well as academic and commercial research organizations.
Company profile, executives and historyLifecore Biomedical stock: common questions
What is Lifecore Biomedical's stock price?
LFCR closed at $6.40 on Nov 12, 2026, up 0.00% on the day. Over the past 52 weeks it traded between $3.63 and $8.98.
What is Lifecore Biomedical's market cap?
Lifecore Biomedical was worth $242.26M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is LFCR's P/E ratio?
Lifecore Biomedical lost money over the twelve months to May 25, 2025 (diluted EPS -$1.27), so it has no meaningful P/E ratio.
How much revenue does Lifecore Biomedical make?
Lifecore Biomedical reported revenue of $128.87M for the twelve months to May 25, 2025, up 0.5% from a year earlier.
Does Lifecore Biomedical pay a dividend?
No. Lifecore Biomedical has not paid a cash dividend over the last twelve months.
How has LFCR stock performed over the past year?
Including dividends, LFCR returned -22.1% over the past year, against +12.0% for the S&P 500.
How many LFCR shares are sold short?
2M shares were sold short at the latest FINRA report, 8.44% of the float, or 3.5 days of average trading volume.
Who are Lifecore Biomedical's competitors?
Companies most similar to Lifecore Biomedical by business, industry and size include MRVI, ELTP, HRTX, RMTI, CYRX.
See a number that looks wrong?